B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $25 to $14.
B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $25 to $14.